Latest News-Ascletis Pharma Inc. Mediaroom_Page

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

- First participants with obesity or overweight with at least one weight-r elatedcomorbidity have b...

2025-07-03 07:00 2684

Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces tha...

2025-06-09 08:15 2507

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dos...

2025-05-20 18:00 3180

Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity

HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral ...

2025-05-06 16:55 3593

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from...

2025-04-23 07:30 3515

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 3...

2025-03-31 19:00 3307

Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025

HONG KONG, March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it...

2025-03-20 19:00 4497

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

* ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of ob...

2025-03-12 07:30 3474

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after ...

2025-02-19 20:00 3865

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

* ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long hal...

2025-01-21 19:00 5672

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

* In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 ...

2024-12-18 21:43 4871

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expe...

2024-11-12 19:30 3582

Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

* Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated lo...

2024-11-07 19:30 4352

Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

- ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once...

2024-09-17 18:25 4394

Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed met...

2024-06-11 08:10 3108

Ascletis Announces Strategic Decisions on FXR agonist ASC42

HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672,...

2024-04-03 17:10 3311

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

HANGZHOU and SHAOXING, China, March 10, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Asc...

2024-03-11 08:10 2864

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascl...

2024-01-24 16:50 4023

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints ...

2024-01-23 12:17 3977

Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-al...

2024-01-02 20:06 4465